Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma | Zendy

Michael Wang | Zendy; Simon Rule | Zendy; Peter Martin | Zendy; André Goy | Zendy; Rebecca Auer | Zendy; Brad S. Kahl | Zendy; Wojciech Jurczak | Zendy; Ranjana H. Advani | Zendy; Jorge Romaguera | Zendy; Michael E. Williams | Zendy; Jacqueline C. Barrientos | Zendy; Ewa Chmielowska | Zendy; John Radford | Zendy; Stephan Stilgenbauer | Zendy; Martin Dreyling | Zendy; W Wiktor-Jędrzejczak | Zendy; Peter Johnson | Zendy; Stephen E. Spurgeon | Zendy; Lei Li | Zendy; Liang Zhang | Zendy; Kate J. Newberry | Zendy; Zhishuo Ou | Zendy; Nancy Cheng | Zendy; Bingliang Fang | Zendy; Jesse McGreivy | Zendy; Fong Clow | Zendy; Joseph J. Buggy | Zendy; Betty Chang | Zendy; Darrin M. Beaupre | Zendy; Lori Kunkel | Zendy; Kristie A. Blum | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

Author(s) -

Michael Wang,

Simon Rule,

Peter Martin,

André Goy,

Rebecca Auer,

Brad S. Kahl,

Wojciech Jurczak,

Ranjana H. Advani,

Jorge Romaguera,

Michael E. Williams,

Jacqueline C. Barrientos,

Ewa Chmielowska,

John Radford,

Stephan Stilgenbauer,

Martin Dreyling,

W Wiktor-Jędrzejczak,

Peter Johnson,

Stephen E. Spurgeon,

Lei Li,

Liang Zhang,

Kate J. Newberry,

Zhishuo Ou,

Nancy Cheng,

Bingliang Fang,

Jesse McGreivy,

Fong Clow,

Joseph J. Buggy,

Betty Chang,

Darrin M. Beaupre,

Lori Kunkel,

Kristie A. Blum

Publication year - 2013

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1306220

Subject(s) - ibrutinib , bruton's tyrosine kinase , mantle cell lymphoma , cancer research , lymphoma , tyrosine kinase , medicine , pathogenesis , immunology , leukemia , receptor , chronic lymphocytic leukemia

Bruton's tyrosine kinase (BTK) is a mediator of the B-cell-receptor signaling pathway implicated in the pathogenesis of B-cell cancers. In a phase 1 study, ibrutinib, a BTK inhibitor, showed antitumor activity in several types of non-Hodgkin's lymphoma, including mantle-cell lymphoma.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research